Burning Rock Biotech (BNR) Accumulated Expenses (2019 - 2026)

Burning Rock Biotech (BNR) has reported Accumulated Expenses for 8 consecutive years, with $10.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 4.07% year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $10.9 million (up 4.07% YoY), while the FY2025 annual figure was $11.6 million, down 5.7% from the prior year.
• Accumulated Expenses came in at $10.9 million for Q1 2026 at Burning Rock Biotech, down from $11.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $24.4 million in Q4 2022, with the low at $10.5 million in Q2 2025.
• Average Accumulated Expenses over 5 years is $14.4 million, with a median of $12.6 million recorded in 2024.
• Across the five-year window, Accumulated Expenses soared 77.94% in 2022 and plunged 44.98% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $24.4 million in 2022, then tumbled by 40.37% to $14.6 million in 2023, then fell by 14.51% to $12.5 million in 2024, then decreased by 8.5% to $11.4 million in 2025, then decreased by 4.15% to $10.9 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $10.9 million, $11.4 million, and $10.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.